On Nov. 23, 2020, the University of Oxford, in collaboration with AstraZeneca, announced interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens In the two different dose regimens vaccine efficacy was 90% in one and 62% in the other